These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10997418)

  • 1. Anti-HIV therapy.
    Geraci AP; Di Rocco A
    AIDS; 2000 Sep; 14(13):2059-61. PubMed ID: 10997418
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels.
    Sha BE; Johnson VA; Kendall MA; Haubrich R; Nokta M; Lamb K; Zackin RA; Nail CD; Currier JS
    AIDS; 2000 Apr; 14(6):746-8. PubMed ID: 10807200
    [No Abstract]   [Full Text] [Related]  

  • 3. Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells.
    Joos B; Fischer M; Opravil M; Ott P; Weber R; Cone RW
    AIDS; 2000 Apr; 14(6):752-4. PubMed ID: 10807203
    [No Abstract]   [Full Text] [Related]  

  • 4. Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
    Flandre P
    AIDS; 1999 Feb; 13(3):430-1. PubMed ID: 10199241
    [No Abstract]   [Full Text] [Related]  

  • 5. Choosing optimal antiretroviral therapies in 2008.
    Laurence J
    AIDS Read; 2008 Nov; 18(11):548-9. PubMed ID: 19062396
    [No Abstract]   [Full Text] [Related]  

  • 6. Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system.
    Delforge ML; Farber CM; De Leener F; Caroyer JM; Liesnard C; Van Vooren JP
    Clin Infect Dis; 1999 Apr; 28(4):931. PubMed ID: 10825078
    [No Abstract]   [Full Text] [Related]  

  • 7. Adherence to triple therapy and viral load response.
    Low-Beer S; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2000 Apr; 23(4):360-1. PubMed ID: 10836763
    [No Abstract]   [Full Text] [Related]  

  • 8. Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000.
    Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children.
    HIV Clin Trials; 2000; 1(3):58-99. PubMed ID: 11590506
    [No Abstract]   [Full Text] [Related]  

  • 9. Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy.
    Orrell C; Kaplan R
    Lancet Infect Dis; 2015 Jul; 15(7):748-9. PubMed ID: 26062879
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
    Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
    AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.
    ;
    HIV Clin Trials; 2000; 1(1):60-110. PubMed ID: 11590490
    [No Abstract]   [Full Text] [Related]  

  • 12. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 16. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
    AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
    Medeiros RP; Munerato P; Diaz RS
    J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
    [No Abstract]   [Full Text] [Related]  

  • 18. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001.
    Panel on Clinical Practices for Treatment of HIV Infection
    HIV Clin Trials; 2001; 2(3):227-306. PubMed ID: 11590532
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.
    Hoesley CJ; Saag MS; Chatham A; Kilby JM
    Clin Infect Dis; 2000 Oct; 31(4):1095-7. PubMed ID: 11049795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.